These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26784539)

  • 1. TAP-ing into TIEPPs for cancer immunotherapy.
    Kiessling R
    J Clin Invest; 2016 Feb; 126(2):480-2. PubMed ID: 26784539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
    Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
    J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.
    Seidel UJ; Oliveira CC; Lampen MH; Hall Tv
    Cancer Immunol Immunother; 2012 Jan; 61(1):119-25. PubMed ID: 22116347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
    Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
    Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.
    Durgeau A; El Hage F; Vergnon I; Validire P; de Montpréville V; Besse B; Soria JC; van Hall T; Mami-Chouaib F
    J Immunol; 2011 Dec; 187(11):5532-9. PubMed ID: 22025554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.
    Hafstrand I; Doorduijn EM; Sun R; Talyzina A; Sluijter M; Pellegrino S; Sandalova T; Duru AD; van Hall T; Achour A
    J Immunol; 2018 Apr; 200(8):2860-2868. PubMed ID: 29507106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
    Marijt KA; Doorduijn EM; van Hall T
    Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
    Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
    Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
    Milano F; Guarriera M; Rygiel AM; Krishnadath KK
    PLoS One; 2010 Aug; 5(8):e12424. PubMed ID: 20865050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer.
    Hafstrand I; Doorduijn EM; Duru AD; Buratto J; Oliveira CC; Sandalova T; van Hall T; Achour A
    J Immunol; 2016 Mar; 196(5):2327-34. PubMed ID: 26800871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
    Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
    Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
    Matsui K; O'Mara LA; Allen PM
    Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population.
    Lampen MH; Verweij MC; Querido B; van der Burg SH; Wiertz EJ; van Hall T
    J Immunol; 2010 Dec; 185(11):6508-17. PubMed ID: 20980626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.
    Oliveira CC; Sluijter M; Querido B; Ossendorp F; van der Burg SH; van Hall T
    Mol Immunol; 2014 Nov; 62(1):129-36. PubMed ID: 24983205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor-specific cytotoxic T lymphocytes.
    El Hage F; Durgeau A; Mami-Chouaib F
    Ann N Y Acad Sci; 2013 Apr; 1283():75-80. PubMed ID: 23302073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas.
    Setiadi AF; David MD; Chen SS; Hiscott J; Jefferies WA
    Cancer Res; 2005 Aug; 65(16):7485-92. PubMed ID: 16103103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.